SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

BioCardia, Inc. – ‘CORRESP’ from 11/15/23

On:  Wednesday, 11/15/23, at 5:17pm ET   ·   Delayed-Release:  Filing  –  Release Delayed   ·   Accession #:  1437749-23-32194

Previous ‘CORRESP’:  ‘CORRESP’ on 11/14/23   ·   Next:  ‘CORRESP’ on 12/1/23   ·   Latest:  ‘CORRESP’ on 3/28/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/15/23  BioCardia, Inc.                   CORRESP1/08/24    1:16K                                    RDG Filings/FA

Comment-Response or Other Letter to the SEC   —   Delayed-Release

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: CORRESP     Comment-Response or Other Letter to the SEC         HTML     15K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  bcda20231114c_corresp.htm  
 C:  <>  <> 

 

BioCardia, Inc.

320 Soquel Way

Sunnyvale, California 94085

 

November 15, 2023

 

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Cindy Polynice

 

 

Re:

BioCardia, Inc.

 

 

Registration  Statement on Form S-3

 

 

File No. 333-275099

 

Ladies and Gentlemen:

 

Reference is made to our letter, filed as correspondence via EDGAR on November 14, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-3 for 4:00 p.m., on November 16, 2023, in accordance with Rule 461 under the Securities Act of 1933, as amended.

 

We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.

 

Please contact our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael J. Danaher at (650) 320-4625 if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

 

[Signature page follows]

 

 

 

 

 

Sincerely,

 

 

 

 

  BioCardia, Inc.  

 

 

 

 

/s/ Peter Altman

 

 

Peter Altman

 

 

President and Chief Executive Officer and

 

  Director  

 

cc:

David McClung, BioCardia, Inc.

 

Michael J. Danaher, Wilson Sonsini Goodrich & Rosati, P.C.

 

Austin D. March, Wilson Sonsini Goodrich & Rosati, P.C.

 

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘CORRESP’ Filing    Date    Other Filings
11/16/238-K
Filed on:11/15/23
11/14/238-K,  CORRESP
 List all Filings 
Top
Filing Submission 0001437749-23-032194   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 1:40:35.2am ET